Sure! Here’s the translation into American English:
Cambridge Isotope Laboratories, Inc. (CIL) and Chemtatva Chiral Solutions Pvt. Ltd. (CCS) have formalized a strategic alliance that will give rise to Cambridge Isotope Laboratories, Pvt. Ltd., a new entity that will be established in Hyderabad, India. This agreement represents a crucial advancement in CIL’s global expansion and aims to optimize the production and supply of isotope-enriched chemical solutions, particularly targeted at the pharmaceutical and electronics sectors.
The new company is expected to be officially established in the fourth quarter of 2025 and will initially operate from CCS’s existing facilities. Additionally, new facilities are anticipated to open in 2026 within Genome Valley, a well-known life sciences cluster on the outskirts of Hyderabad. This partnership not only seeks to strengthen the global supply chain but will also provide real-time support to customers in Asia, ensuring the continuity of operations worldwide.
Cliff Caldwell, CEO of CIL, expressed his enthusiasm for this collaboration, emphasizing that the merger of both companies will enable the development of large-scale technologies and enhance support for both pharmaceutical and industrial applications. Caldwell stated that this initiative reflects CIL’s commitment to global research and development in relevant scientific areas.
On his part, Vishal Rajput, CEO of CCS, highlighted that the new entity will benefit from CCS’s robust infrastructure and technical capabilities, while integrating CIL’s international standards in isotopic chemistry and logistics. Rajput will lead the new company while maintaining CCS’s traditional business, with the ambition of expanding access to high-quality compounds, both isotope-labeled and non-labeled.
It has been ensured that all products under the CIL, Eurisotop, and CCS brands will remain available through existing channels in India and globally. More details about the launch and operations of Cambridge Isotope Laboratories, Pvt. Ltd. are expected to be disclosed in the coming months.
CIL, part of the Otsuka Pharmaceutical group in Japan, stands out as the largest global manufacturer and supplier of stable isotopes, consolidating over 40 years of industry experience. CCS, founded in 2021, specializes in chiral chemistry and custom synthesis, positioning itself as a reliable partner in the life sciences field by offering innovative solutions to complex problems.
Source: MiMub in Spanish